Silence Therapeutics aims to use the database to help identify new drug targets, as well as for patient recruitment and stratification in clinical trials.
Cambridge Cancer Genomics will contribute AI, liquid biopsy technology, and a TMB sequencing panel to broaden access to cancer immunotherapies in the UK.
The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.
The analytics firm formerly known as Quintiles IMS will offer researchers secure access to Genomics England's de-identified databases in pursuit of precision medicine.
As of this week, the project had sequenced 39,500 genomes and returned reports for about 3,000 rare disease families and more than 600 cancer patients.
Fabric disclosed partnerships with Rady Children's Institute for Genomic Medicine, the Utah Genome Project, and Genomics England's 100,000 Genomes Project.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
